{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:45:15Z","timestamp":1791499515499,"version":"4.3.4"},"reference-count":20,"publisher":"American Association of Zoo Veterinarians","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Zoo and Wildlife Medicine"],"published-print":{"date-parts":[[2023,3,20]]},"DOI":"10.1638\/2022-0022","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T15:04:10Z","timestamp":1679324650000},"source":"Crossref","is-referenced-by-count":2,"title":["NALTREXONE AS A PROMISING TREATMENT FOR CLINICAL SIGNS OF LATERAL LINE DEPIGMENTATION IN PALETTE SURGEONFISH (PARACANTHURUS HEPATUS)"],"prefix":"10.1638","volume":"54","author":[{"given":"Megan M.","family":"Strobel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra C.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisa N.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Hepps Keeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Lewbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1213","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"TS Arnold, LA Wittenburg, CC Powell,  \"Vet Ophthal.\"  17, \"Effect of topical naltrexone 0.3% on corneal sensitivity and tear parameters in normal brachycephalic dogs.\" 328 (2014)","DOI":"10.1111\/vop.12079"},{"key":"2","unstructured":"GC. Blasiola,  \"Bull Inst Oceanogr.\"  5, \"Description, preliminary studies and probable etiologies of head and lateral line erosion (HLLE) of the palette tang, Paracanthurus hepatus (Linnaeus, 1758) and other Acanthurids.\" 255 (1989)"},{"key":"3","doi-asserted-by":"crossref","unstructured":"J Blebea, JH Vu, S Assadnia, et al.  \"J Vasc Surg.\"  35, \"Differential effects of vascular growth factors on arterial and venous angiogenesis.\" 532 (2002)","DOI":"10.1067\/mva.2002.120042"},{"key":"4","unstructured":"L Croft, R Francis-Floyd, BD Petty, et al.  \"Proc Int Assoc Aquatic Anim Med.\"  \"The effect of dietary vitamin C levels on the development of Head and Lateral Line Erosion Syndrome (HLLES) in ocean surgeonfish.\" (2005)"},{"key":"5","doi-asserted-by":"crossref","unstructured":"NG Dannemiller, MR O'Connor, WG Van Bonn,  \"J Am Vet Med Assoc.\"  259, \"An integrative review of lateral line depigmentation in marine and freshwater fish.\" 617 (2021)","DOI":"10.2460\/javma.259.6.617"},{"key":"6","doi-asserted-by":"crossref","unstructured":"GJ Fleming, A Corwin, AJ McCoy, et al.  \"J Zoo Wildl Med.\"  39, \"Treatment factors influencing the use of recombinant platelet-derived growth factor (Regranex\u00ae) for head and lateral line erosion syndrome in ocean surgeonfish (Acanthurus bahianus).\" 155 (2008)","DOI":"10.1638\/2007-0045R.1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"CA. Hadfield,  \"Clinical guide to fish medicine.\"  \"Noninfectious diseases (other\" 378 (2021)","DOI":"10.1002\/9781119259886.ch23"},{"key":"8","doi-asserted-by":"crossref","unstructured":"J Hemdal  and RA Odum  \"N Am J Aquacult.\"  73, \"The role of activated lignite carbon in the development of head and lateral line erosion in the ocean surgeon.\" 489 (2010)","DOI":"10.1080\/15222055.2011.635781"},{"key":"9","doi-asserted-by":"crossref","unstructured":"JA Immonen, IS Zagon, GS Lewis, et al.  \"Exp Biol Med (Maywood).\"  238, \"Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.\" 1127 (2013)","DOI":"10.1177\/1535370213502632"},{"key":"10","doi-asserted-by":"crossref","unstructured":"JA Immonen, IS Zagon, PJ McLaughlin,  \"Exp Biol Med (Maywood).\"  239, \"Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.\" 1300 (2014)","DOI":"10.1177\/1535370214543061"},{"key":"11","unstructured":"J Jaros  and P Lio  \"J Drugs Dermatol.\"  18, \"Low dose naltrexone in dermatology.\" 235 (2019)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"M Levesque, Y Feng, RA Jones, et al.  \"Dis Models Mechanisms.\"  6, \"Inflammation drives wound hyperpigmentation in zebrafish by recruiting pigment cells to sites of tissue damage.\" 508 (2013)","DOI":"10.1242\/dmm.010371"},{"key":"13","doi-asserted-by":"crossref","unstructured":"PJ McLaughlin, JD Cain, MB Titunick, et al.  \"Adv Wound Care.\"  6, \"Topical naltrexone is a safe and effective alternative to standard treatment of diabetic wounds.\" 279 (2017)","DOI":"10.1089\/wound.2016.0725"},{"key":"14","doi-asserted-by":"crossref","unstructured":"PJ McLaughlin, JA Immonen, IS Zagon,  \"Exp Biol Med.\"  238, \"Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis.\" 733 (2013)","DOI":"10.1177\/1535370213492688"},{"key":"15","doi-asserted-by":"crossref","unstructured":"EJ. Noga,  \"Fish disease: diagnosis and treatment.\"  \"Problem 100, chapter 14: lateral line depigmentation.\" 333 (2010)","DOI":"10.1002\/9781118786758"},{"key":"16","doi-asserted-by":"crossref","unstructured":"L Parkitny  and J Younger  \"Biomedicines.\"  5, \"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia.\" 16 (2017)","DOI":"10.3390\/biomedicines5020016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"MA Stamper, MM Kittell, EE Patel, et al.  \"J Aquatic Anim Health.\"  23, \"Effects of full-stream carbon filtration on the development of Head and Lateral Line Erosion Syndrome (HLLES) in ocean surgeon.\" 111 (2011)","DOI":"10.1080\/08997659.2011.608608"},{"key":"19","doi-asserted-by":"crossref","unstructured":"K Toljan  and B Vrooman  \"Med Sci.\"  6, \"Low-dose naltrexone: review of therapeutic utilization.\" 1 (2018)","DOI":"10.3390\/medsci6040082"},{"key":"20","doi-asserted-by":"crossref","unstructured":"J Younger, L Parkitny, D McClain,  \"Clin Rheumatol.\"  33, \"The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain.\" 451 (2014)","DOI":"10.1007\/s10067-014-2517-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"CA Schneider, WS Rasband, KW Eliceiri,  \"Nat Methods.\"  9, \"NIH Image to ImageJ: 25 years of image analysis.\" 671 (2012)","DOI":"10.1038\/nmeth.2089"}],"container-title":["Journal of Zoo and Wildlife Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T15:04:21Z","timestamp":1679324661000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/journal-of-zoo-and-wildlife-medicine\/volume-54\/issue-1\/2022-0022\/NALTREXONE-AS-A-PROMISING-TREATMENT-FOR-CLINICAL-SIGNS-OF-LATERAL\/10.1638\/2022-0022.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1638\/2022-0022","relation":{},"ISSN":["1042-7260"],"issn-type":[{"value":"1042-7260","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}